<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03270228</url>
  </required_header>
  <id_info>
    <org_study_id>NSP</org_study_id>
    <nct_id>NCT03270228</nct_id>
  </id_info>
  <brief_title>Natural History of Nonspecific Pleuritis Diagnosed After Video-assisted-thoracoscopic-surgery</brief_title>
  <official_title>Natural History of Nonspecific Pleuritis Diagnosed After Video-assisted-thoracoscopic-surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Naestved Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Naestved Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators want to determine the incidence of malignant disease, type of malignant&#xD;
      disease and overall survival in patients diagnosed with NSP after VATS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Using Landspatientregisteret (LPR) (the National Patient register) the investigators will&#xD;
      identify patients who have received a thoracoscopic pleural-biopsy using the SKS-codes KGAC01&#xD;
      and/or KGAA31 and/or KGAC00. From LPR and Cancerregisteret (the National Cancer-register) the&#xD;
      investigators will receive diagnosis and additional descriptive data. From&#xD;
      dødsårsagsregisteret (the National cause-of-death-register) death date and further&#xD;
      descriptive data will be acquired.&#xD;
&#xD;
      Patients with NSP will be identified as patients with no diagnosis six months after&#xD;
      pleural-biopsy, despite a thorough investigation.&#xD;
&#xD;
      Patients with a malignant effusion and non-malignant effusion (with known cause) will be used&#xD;
      for survival analysis and comparison.&#xD;
&#xD;
      Data Data will be registered in the individual patients CRF (Case Report File) (digital) and&#xD;
      will be transferred to a database-program for further processing. Background-variables will&#xD;
      be used to describe the study population. Only study-coordinators will have access to data.&#xD;
      All data including back-up will be stored and kept in a locked cupboard in a locked room.&#xD;
      Only study coordinators possess relevant keys.&#xD;
&#xD;
      Statistics The investigators define significance level (α) as 0.05, and power (β) as 0.80.&#xD;
      Descriptive data will be analysed using nonparametric statistics: Chi2-test for categorical&#xD;
      data and Mann-Whitney for discrete data. Statistical significance is defined as: p-value &lt;&#xD;
      0.05.&#xD;
&#xD;
      The overall survival of patients with NSP will be analysed using a Caplan-Meier plot and&#xD;
      comparison of NSP patients to patients with malignant pleural-effusion the investigators use&#xD;
      the Logrank test.&#xD;
&#xD;
      All statistical tests is conducted using STATA14 (4905 Lakeway Dr., College Station, TX&#xD;
      77845).&#xD;
&#xD;
      Ethics This study will not require the approval from Videnskabsetisk komité (the Health&#xD;
      Research Ethics Committee), but approval will be sought from Datatilsynet (the Danish Data&#xD;
      Protection Agency).&#xD;
&#xD;
      All results will be stored and analysed by computer, and the patients' anonymity will be&#xD;
      secured according to the national laws. The data will be stored (anonymised), after&#xD;
      completion of the study: data containing cpr.-numbers will be stored behind double-lock at&#xD;
      the department.&#xD;
&#xD;
      No patients or investigators have economic incentives for completing the project.&#xD;
&#xD;
      Economy&#xD;
&#xD;
      Expenses related to gathering of data including contact with LPR, Dødsårsagsregisteret and&#xD;
      the Danish Cancer Register are already financed through primary investigators PhD-project.&#xD;
&#xD;
      Publication The results from the study will be presented at international scientific&#xD;
      congresses and published in international journals. Positive as well as negative results will&#xD;
      be published. The scientists right to freely publish the results cannot be limited. All&#xD;
      information will be passed anonymously.&#xD;
&#xD;
      The order of authors will follow the Vancouver Declaration, and will thus reflect the amount&#xD;
      and significance of work relevant to the specific manuscript.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Actual">January 30, 2019</completion_date>
  <primary_completion_date type="Actual">January 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of cancer</measure>
    <time_frame>10 years</time_frame>
    <description>Percentage</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Type of cancer</measure>
    <time_frame>10 years</time_frame>
    <description>Lung cancer, mesothelioma etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival of patients</measure>
    <time_frame>10 years</time_frame>
    <description>Comparison of patients with a benign cause, a malignant cause and nonspecific pleuritis</description>
  </secondary_outcome>
  <enrollment type="Actual">10000</enrollment>
  <condition>Pleural Effusion Due to Another Disorder (Disorder)</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nonspecific pleuritis after VATS thoracoscopy</intervention_name>
    <description>Patients with a pleural effusion with unknown origin after a VATS thoracoscopy is classified as nonspecific pleuritis.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with a VATS thoracoscopy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients with a VATS thoracoscopy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Simon Reuter, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Naestved Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Naestved Hospital</name>
      <address>
        <city>Naestved</city>
        <zip>4700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 30, 2017</study_first_submitted>
  <study_first_submitted_qc>August 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 1, 2017</study_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Naestved Hospital</investigator_affiliation>
    <investigator_full_name>Simon Reuter</investigator_full_name>
    <investigator_title>Ph.d.-Student</investigator_title>
  </responsible_party>
  <keyword>Incidence of cancer</keyword>
  <keyword>Survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pleural Effusion</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

